Nikayin, Sina
Sanacora, Gerard http://orcid.org/0000-0003-3722-8829
Article History
Accepted: 19 July 2021
First Online: 7 September 2021
Declarations
:
: Funding supporting this work was provided by George D. Gross and Esther S. Gross Endowment and Yale New Haven Health.
: Dr. Nikayin has no disclosures to report. Dr. Sanacora has received consulting fees from Alkermes, Allergan, AstraZeneca, Avanier Pharmaceuticals, Axsome Therapeutics, Biohaven Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Clexio Biosciences, Denovo Biopharma, EMA Wellness, Engrail, Gilgamesh, Hoffmann-La Roche, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Minerva Neurosciences, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, Vistagen Therapeutics, and XW Labs. He has also received research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson and Johnson, Hoffmann-La Roche, Merck, Naurex, Servier Pharmaceuticals, and Usona. No-cost medication was provided to Dr. Sanacora for a National Institutes of Health-sponsored study by Sanofi-Aventis. In addition, he holds shares in Biohaven Pharmaceuticals Holding Company and is a co-inventor on the patent “Glutamate agents in the treatment of mental disorders” (patent 8778979), and a filed patent for using mTOR inhibitors to augment the effects of antidepressants (filed on 20 August, 2018). Yale University, Dr. Sanacora’s and Dr. Nikayin’s institution, has a financial relationship with Janssen Pharmaceuticals and may receive financial benefits from this relationship.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Dr Nikayin and Dr Sanacora contributed to the concept and design of the review and to the writing of the manuscript, approved the final version of the manuscript for submission/publication, and agree to be accountable for the work.